Plaintiff Cephalon, Inc. ("Cephalon") is the owner of U.S. Patent No. 6,264,981 ("the '981 patent"). Cephalon is the holder of an approved New Drug Application ("NDA")1 for the manufacture and sale of fentanyl buccal tablets for the treatment of breakthrough cancer pain. Defendants Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc...
Let's get started
Welcome to the leading source of independent legal reporting Sign on now to see your case. Or view more than 10 million decisions and orders.
Updated daily.
Uncompromising quality.
Complete, Accurate, Current.
Listed below are the cases that are cited in this Featured Case. Click the citation to see the full
text of the cited case. Citations are also linked in the body of the Featured Case.
Cited Cases
No Cases Found
Listed below are those cases in which this Featured Case is cited. Click on the case name to see the
full text of the citing case.